- Home
- DTSS vs APRE Comparison
DTSS vs APRE Comparison
Compare DTSS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- APRE
- Stock Information
- Founded
- DTSS 2014
- APRE 2006
- Country
- DTSS China
- APRE United States
- Employees
- DTSS N/A
- APRE N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTSS Technology
- APRE Health Care
- Exchange
- DTSS Nasdaq
- APRE Nasdaq
- Market Cap
- DTSS 14.2M
- APRE 8.2M
- IPO Year
- DTSS N/A
- APRE 2019
- Fundamental
- Price
- DTSS $2.13
- APRE $1.59
- Analyst Decision
- DTSS
- APRE Strong Buy
- Analyst Count
- DTSS 0
- APRE 2
- Target Price
- DTSS N/A
- APRE $15.50
- AVG Volume (30 Days)
- DTSS 53.5K
- APRE 30.3K
- Earning Date
- DTSS 05-12-2025
- APRE 05-13-2025
- Dividend Yield
- DTSS N/A
- APRE N/A
- EPS Growth
- DTSS N/A
- APRE N/A
- EPS
- DTSS N/A
- APRE N/A
- Revenue
- DTSS $47,284,153.00
- APRE $1,502,581.00
- Revenue This Year
- DTSS N/A
- APRE N/A
- Revenue Next Year
- DTSS N/A
- APRE N/A
- P/E Ratio
- DTSS N/A
- APRE N/A
- Revenue Growth
- DTSS 117.51
- APRE 157.63
- 52 Week Low
- DTSS $1.63
- APRE $1.41
- 52 Week High
- DTSS $8.56
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- DTSS 55.94
- APRE 35.54
- Support Level
- DTSS $1.84
- APRE $1.41
- Resistance Level
- DTSS $2.27
- APRE $1.59
- Average True Range (ATR)
- DTSS 0.15
- APRE 0.11
- MACD
- DTSS 0.03
- APRE 0.04
- Stochastic Oscillator
- DTSS 78.13
- APRE 45.88
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.